Rx00049 - Bromocriptine


Name:
Bromocriptine
Rx ID:
Rx00049
Validation Level:
Phenomic Similarity:
0.532
Reference ID:
DB01200
Primary Indications:
Parkinson's disease; Galactorrhea; Hyperprolactinemia
Orphan Indications:
No annotated orphan indications.
Rare Indications:
No annotated rare indications.
Common Indications:
Diabetes mellitus
Pathways:
Monoamine GPCRs; Amine ligand-binding receptors; GPCRs, Class A Rhodopsin-like; Nalbuphine Action Pathway; Heroin Action Pathway; Levomethadyl Acetate Action Action Pathway; Levallorphan Action Pathwa ...Click to show more
Drug Interactions:
Acetophenazine; Alimemazine; Chlorpromazine; Desvenlafaxine; Erythromycin; Ethopropazine; Fluphenazine; Josamycin; Mesoridazine; Methdilazine; ...
Click to show more...
Food Interactions:
Avoid alcohol. Take with food to reduce irritation.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00049
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
Parkinson's disease Diabetes mellitus 1329 7763 123001 5.616 0 0.0

Chemical, Pharmacological and Biological Annotations


ATC Code:
G02CB01 N04BC01;
Brands:
Apo-Bromocriptine (Apotex); Bagren (Serono (Brazil)); Ergoset; Parlodel Snaptabs (Novartis); Pravidel (Meda (Germany, Sweden), Novartis (Canada, discontinued))
Categories:
Hormone Antagonists; Antiparkinson Agents; Dopamine Agonists; Antidyskinetics
ChEBI ID:
3181
PubChem ID:
31101
KEGG Drug ID:
D03165
SMILE:
[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
InChI:
1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Alkaloids and Derivatives
Class:
Ergolines and Derivatives
Subclass:
Lysergic Acids and Derivatives
Indication:
For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acr...
Click to show more...
Pharmacodynamics:
Bromocriptine stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily co...
Click to show more...
Description:
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and ma...
Click to show more...
Mechanism:
The dopamine D<sub>2</sub> receptor is a 7-transmembrane G-protein coupled receptor associated with G<sub>i</sub> proteins. In lactotrophs, stimulation of dopamine D<sub>2</sub> receptor causes inhibition of adenylyl cyclase, which decrease...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
-
Caco-2 permeable:
-
P-glycoprotein substrate:
Substrate
P-glycoprotein inhibitor I:
Inhibitor
P-glycoprotein inhibitor II:
Inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Inhibitor
CYP450 inhibitory promiscuity:
High CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.7499 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org